Altimmune, Inc. (NasdaqGM: ALT)
Health Care · Biotechnology · US
$2.12
-2.30% today · -46.5% 1Y
Altimmune, Inc. (NasdaqGM: ALT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $412.38M and employs 57 people.
Over the last twelve months the share price has lost 46.5%, trading between 2.17 and 6.44.
Tweenvest scores Altimmune, Inc. across four factors: quality 37/100, value 33/100. Its strongest factor is quality.
ALT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $412.38M
- Revenue (TTM)
- $31.00K
- P/E
- —
- EPS
- -0.73
- Dividend yield
- —
- Beta (5Y)
- 0.06
- 52-week high
- $6.44
- 52-week low
- $2.17
- Avg volume (3M)
- —
- Shares outstanding
- 194.52M
- Employees
- 57
- Next earnings
- —
About Altimmune, Inc.
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
- ISIN
- US02155H2004
- Founded
- 1997
- Listed since
- May 26, 2017
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Ovid Therapeutics Inc.NasdaqCM: OVID | $421.84M | $2.16 | -8.86% |
| YD Bio LimitedNasdaqGM: YDES | $419.32M | $5.92 | -12.04% |
| Edding Genor Group Holdings LimitedSEHK: 6998 | $418.87M | HK$1.65 | -3.24% |
| Beijing Kawin Technology Share-Holding Co., Ltd.SHSE: 688687 | $412.63M | CN¥16.49 | -10.04% |
| Autolus Therapeutics plcNasdaqGS: AUTL | $409.89M | $1.54 | -2.53% |
| DiaMedica Therapeutics Inc.NasdaqCM: DMAC | $408.22M | $7.57 | -9.12% |
| Tectonic Therapeutic, Inc.NasdaqGM: TECX | $403.69M | $20.65 | -11.49% |
| AVITA Medical, Inc.NasdaqCM: RCEL | $403.29M | $13.04 | -1.29% |
Figures last refreshed Oct 18, 2026.